HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brand, C. L. Articles by Holst, J. J. Search for Related Content PubMed PubMed Citation Articles by Brand, C. L. Articles by Holst, J. J. Social Bookmarking                What's this?

Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits

Effects of glucagon immunoneutralization on plasma glucose, insulin, and glucagon were studied 2-4 h after intravenous injection of a high-affinity, monoclonal glucagon antibody into normal as well as moderately and severely alloxan (ALX)-induced diabetic rabbits (n = 5-7). A monoclonal trinitrophenyl antibody was used in control studies. Endogenous glucagon was completely neutralized as evidenced by undetectable levels of free glucagon and high plasma glucagon-binding capacities. In postabsorbtive normal rabbits, glucagon neutralization decreased plasma glucose by 2.2 +/- 0.3 mmol/l, and the resulting plasma levels of insulin and glucagon (indirectly measured) were 8 +/- 3 and 640 +/- 129% of baseline, respectively. However, when euglycemia was maintained by means of glucose infusion (steady-state plasma glucose and glucose infusion rate: 6.6 +/- 0.1 mmol/l and 3.0 +/- 0.4 mg.kg-1.min-1), both plasma insulin and glucagon remained unaltered. Thus, the glucose infusion rate accurately reflects glucagon's contribution to postabsorbtive glucose production. In both moderately and severely diabetic rabbits, immunoneutralization of glucagon decreased plasma glucose by approximately 8 mmol/l, leading to euglycemia (7.3 +/- 1.1 mmol/l) and reduced hyperinsulinemia (41 +/- 9% of baseline) in the former and to partial restoration of euglycemia (12.7 +/- 1.8 mmol/l) and unchanged insulin levels in the latter group of diabetic rabbits (P < 0.05 vs. controls in all studies). No significant changes were observed in control studies. In conclusion, glucagon is an important regulator of postabsorbtive glucose production in normal rabbits and plays an important role in the maintenance of hyperglycemia in ALX-induced diabetic rabbits.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				B. E. Dunning and J. E. Gerich The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications Endocr. Rev., May 1, 2007; 28(3): 253 - 283. [Abstract] [Full Text] [PDF]

				H. Sorensen, C. L. Brand, S. Neschen, J. J. Holst, K. Fosgerau, E. Nishimura, and G. I. Shulman Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice. Diabetes, October 1, 2006; 55(10): 2843 - 2848. [Abstract] [Full Text] [PDF]

				B. Raju and P. E. Cryer Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E181 - E186. [Abstract] [Full Text] [PDF]

				M. J. Christopher, C. Rantzau, G. McConell, B. E. Kemp, and F. P. Alford Prevailing hyperglycemia is critical in the regulation of glucose metabolism during exercise in poorly controlled alloxan-diabetic dogs J Appl Physiol, March 1, 2005; 98(3): 930 - 939. [Abstract] [Full Text] [PDF]

				S. A. Qureshi, M. Rios Candelore, D. Xie, X. Yang, L. M. Tota, V. D.-H. Ding, Z. Li, A. Bansal, C. Miller, S. M. Cohen, et al. A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects Diabetes, December 1, 2004; 53(12): 3267 - 3273. [Abstract] [Full Text] [PDF]

				G. Jiang and B. B. Zhang Glucagon and regulation of glucose metabolism Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E671 - E678. [Abstract] [Full Text] [PDF]

				R. W. Gelling, X. Q. Du, D. S. Dichmann, J. Romer, H. Huang, L. Cui, S. Obici, B. Tang, J. J. Holst, C. Fledelius, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice PNAS, February 4, 2003; 100(3): 1438 - 1443. [Abstract] [Full Text] [PDF]

				M. Furuta, H. Yano, A. Zhou, Y. Rouille, J. J. Holst, R. Carroll, M. Ravazzola, L. Orci, H. Furuta, and D. F. Steiner Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2 PNAS, June 24, 1997; 94(13): 6646 - 6651. [Abstract] [Full Text] [PDF]

				M. Furuta, A. Zhou, G. Webb, R. Carroll, M. Ravazzola, L. Orci, and D. F. Steiner Severe Defect in Proglucagon Processing in Islet A-cells of Prohormone Convertase 2 Null Mice J. Biol. Chem., July 13, 2001; 276(29): 27197 - 27202. [Abstract] [Full Text] [PDF]